Rhein-Emodin Combination Activates UQCRC1 to Attenuate MPP+-Induced Ferroptosis in Dopaminergic Neurons

  • Chem Biodivers. 2026 Mar;23(3):e02053. doi: 10.1002/cbdv.202502053.
Ayiguzhali Yusun  1  2 Hongmei Wan  1 Shuang Li  3 Yanping Liu  1 Huaxian Chen  1 Mo Sun  4 Xudong Ding  1 Chenning Zhang  1
Affiliations
  • 1. Department of Rehabilitation Medicine, Postgraduate Union Training Base of Xiangyang No.1 People's Hospital, School of Medicine, Wuhan University of Science and Technology, Xiangyang, Hubei, China.
  • 2. Department of Rehabilitation Medicine, The 947th Army Hospital of the Chinese PLA, Kashgar, China.
  • 3. Department of Child Health Care, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang, China.
  • 4. School of Biological Sciences, Georgia Institute of Technology, Atlanta, Georgia, USA.
Abstract

Ferroptosis plays a critical role in Parkinson's disease (PD). This study investigates the neuroprotective effect of a combination of two natural Anthraquinones, rhein and emodin, against Ferroptosis, focusing on the mitochondrial complex III subunit UQCRC1. Using network pharmacology and experimental validation in erastin/MPP+-induced PC12 cells, we found that the optimal rhein-emodin combination potently inhibited ferroptotic cell death. This effect was associated with restored mitochondrial function, reduced lipid peroxidation, and the coordinated regulation of ferroptosis-related proteins, including the upregulation of GPX4 and FTH and downregulation of ACSL4. Crucially, the co-treatment markedly activated UQCRC1 expression. Furthermore, UQCRC1 knockdown abolished these anti-ferroptotic effects, establishing it as an essential mediator. Our findings demonstrate that the rhein-emodin combination attenuates Ferroptosis primarily through UQCRC1 activation, highlighting its therapeutic promise and identifying UQCRC1 as a novel regulatory node for PD intervention.

Keywords
Parkinson's disease; UQCRC1; ferroptosis; network pharmacology; rhein–emodin.
Products